Literature DB >> 10779703

Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity.

A J Morton1, W Leavens.   

Abstract

The mechanism underlying the pathology of Huntington's disease (HD) is unknown, although there is substantial evidence supporting a role for excitotoxicity. The discovery of abnormal aggregations of protein in the brains of patients with HD, as well as in the brains of transgenic mice modeling this disease, has led to the suggestion that these "inclusions" have a pathogenic role. However, the relationship between inclusion formation and the progressive neurodegeneration in HD remains unclear. Here, we used mice transgenic for the first exon of the HD gene and an expanded CAG repeat (R6/2 line) to examine the role of neuronal intranuclear inclusions in kainic acid (KA) excitotoxicity. Unexpectedly, we found that the toxicity of KA was markedly attenuated in R6/2 mice compared with wild-type mice. In particular, the number and severity of KA-induced seizures in R6/2 mice was significantly reduced. When seizures occurred in 3-week-old R6/2 mice, we found lesions in the CA3 region of the hippocampus. However, neuronal intranuclear inclusions were not induced by KA in 3-week-old mice. Further, in older mice (9 weeks), the pre-existence of inclusions in CA3 neurons did not increase the vulnerability of neurons to KA, since no lesions were seen in 9-week R6/2 mouse brain. Our results suggest that an increased susceptibility to excitotoxic stimuli does not underlie the early phase of the neurological phenotype in R6/2 mice, although a role in later stages is not excluded by our findings. The significance of these findings is discussed in the context of the R6/2 mouse as a model for HD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779703     DOI: 10.1016/s0361-9230(00)00238-0

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  13 in total

Review 1.  Killer proteases and little strokes--how the things that do not kill you make you stronger.

Authors:  Anne E O'Duffy; Yvette M Bordelon; BethAnn McLaughlin
Journal:  J Cereb Blood Flow Metab       Date:  2006-08-09       Impact factor: 6.200

2.  Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum.

Authors:  Mai T Dang; Fumiaki Yokoi; Henry H Yin; David M Lovinger; Yanyan Wang; Yuqing Li
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

3.  Glycolysis inhibition decreases the levels of glutamate transporters and enhances glutamate neurotoxicity in the R6/2 Huntington's disease mice.

Authors:  Ana María Estrada-Sánchez; Teresa Montiel; Lourdes Massieu
Journal:  Neurochem Res       Date:  2010-04-18       Impact factor: 3.996

Review 4.  The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.

Authors:  Jia Yi Li; Natalija Popovic; Patrik Brundin
Journal:  NeuroRx       Date:  2005-07

Review 5.  The corticostriatal pathway in Huntington's disease.

Authors:  Carlos Cepeda; Nanping Wu; Véronique M André; Damian M Cummings; Michael S Levine
Journal:  Prog Neurobiol       Date:  2006-12-13       Impact factor: 11.685

6.  Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.

Authors:  Carlos Cepeda; Raymond S Hurst; Christopher R Calvert; Elizabeth Hernández-Echeagaray; Oanh K Nguyen; Emily Jocoy; Lindsey J Christian; Marjorie A Ariano; Michael S Levine
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

7.  Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.

Authors:  Rona K Graham; Mahmoud A Pouladi; Prasad Joshi; Ge Lu; Yu Deng; Nan-Ping Wu; Bryan E Figueroa; Martina Metzler; Véronique M André; Elizabeth J Slow; Lynn Raymond; Robert Friedlander; Michael S Levine; Blair R Leavitt; Michael R Hayden
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

8.  Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Authors:  Hua Zhang; Qin Li; Rona K Graham; Elizabeth Slow; Michael R Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2008-04-16       Impact factor: 5.996

Review 9.  Targeting glial cells to elucidate the pathogenesis of Huntington's disease.

Authors:  Han-Yun Hsiao; Yijuang Chern
Journal:  Mol Neurobiol       Date:  2010-01-28       Impact factor: 5.590

10.  Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington's disease.

Authors:  Jonathan Wanderer; A Jennifer Morton
Journal:  Histochem Cell Biol       Date:  2007-02-07       Impact factor: 2.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.